Selexipag in the treatment of pulmonary arterial hypertension

Design, development, and therapy

Elizabeth Ashley Hardin, Kelly M. Chin

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.

Original languageEnglish (US)
Pages (from-to)3747-3754
Number of pages8
JournalDrug Design, Development and Therapy
Volume10
DOIs
StatePublished - Nov 15 2016

Fingerprint

Pulmonary Hypertension
Epoprostenol Receptors
Phase III Clinical Trials
Phase II Clinical Trials
Epoprostenol
Vasoconstriction
Pulmonary Artery
Prostaglandins
Smooth Muscle Myocytes
Thrombosis
Hemodynamics
Therapeutics
selexipag
Vascular Remodeling

Keywords

  • Prostacyclin
  • Pulmonary arterial hypertension
  • Selexipag

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Selexipag in the treatment of pulmonary arterial hypertension : Design, development, and therapy. / Hardin, Elizabeth Ashley; Chin, Kelly M.

In: Drug Design, Development and Therapy, Vol. 10, 15.11.2016, p. 3747-3754.

Research output: Contribution to journalReview article

@article{1bf1b9dd4ef1426bb78c54ddc8517406,
title = "Selexipag in the treatment of pulmonary arterial hypertension: Design, development, and therapy",
abstract = "Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.",
keywords = "Prostacyclin, Pulmonary arterial hypertension, Selexipag",
author = "Hardin, {Elizabeth Ashley} and Chin, {Kelly M.}",
year = "2016",
month = "11",
day = "15",
doi = "10.2147/DDDT.S103534",
language = "English (US)",
volume = "10",
pages = "3747--3754",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Selexipag in the treatment of pulmonary arterial hypertension

T2 - Design, development, and therapy

AU - Hardin, Elizabeth Ashley

AU - Chin, Kelly M.

PY - 2016/11/15

Y1 - 2016/11/15

N2 - Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.

AB - Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries including increased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase II clinical trial and reduce clinical worsening in a large phase III clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the prostacyclin signaling pathway, currently available oral prostanoid medications, and the development and clinical use of selexipag.

KW - Prostacyclin

KW - Pulmonary arterial hypertension

KW - Selexipag

UR - http://www.scopus.com/inward/record.url?scp=85003510877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003510877&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S103534

DO - 10.2147/DDDT.S103534

M3 - Review article

VL - 10

SP - 3747

EP - 3754

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -